RASNA THERAPEUTICS, INC. (OTCMKTS:RASP) Files An 8-K Other Events

RASNA THERAPEUTICS, INC. (OTCMKTS:RASP) Files An 8-K Other Events
Item 8.01 Other Events.

On May 8, 2017, Rasna Therapeutics, Inc. issued a press release announcing an update on the development of formulated RASP-101, a novel modality for treatment of NPM1-mutated acute myeloid leukemia (AML).
The press release is attached as Exhibit 99.1 to this report on Form 8-K and is incorporated herein by reference.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
99.1 Rasna Therapeutics, Inc. Press Release dated May 8, 2017.

About RASNA THERAPEUTICS, INC. (OTCMKTS:RASP)

Rasna Therapeutics, Inc., formerly Active With Me Inc., creates online resources that offer travelers information on activity-based travel. The Company’s Website focuses on offering third-party content and information to visitors in their activity of choice. The Company’s Website also focuses on offering links to clubs and organizations. The Company is in development-stage. Rasna DE is the subsidiary of the Company. Rasna DE is engaged in modulating the molecular targets nucleophosmin gene (NPM1) and lysine (K)-specific demethylase 1A (LSD1), which are implicated in the disease progression of leukemia and lymphoma. The Company focuses on performing preclinical research on NPM1 and LSD1. As of June 30, 2016, the Company had not generated any revenues.

RASNA THERAPEUTICS, INC. (OTCMKTS:RASP) Recent Trading Information

RASNA THERAPEUTICS, INC. (OTCMKTS:RASP) closed its last trading session 00.00 at 1.50 with shares trading hands.

An ad to help with our costs